Literature DB >> 21420376

Influence of trypanocidal therapy on the haematology of vervet monkeys experimentally infected with Trypanosoma brucei rhodesiense.

Maina Ngotho1, John M Kagira, Christopher Kariuki, Naomi Maina, John K Thuita, David M Mwangangi, Idle O Farah, Jann Hau.   

Abstract

The aim of this study was to characterise the sequential haematological changes in vervet monkeys infected with Trypanosoma brucei rhodesiense and subsequently treated with sub-curative diminazene aceturate (DA) and curative melarsoprol (MelB) trypanocidal drugs. Fourteen vervet monkeys, on a serial timed-kill pathogenesis study, were infected intravenously with 10(4) trypanosomes of a stabilate T. b. rhodesiense KETRI 2537. They were treated with DA at 28 days post infection (dpi) and with MelB following relapse of infection at 140 dpi. Blood samples were obtained from the monkeys weekly, and haematology conducted using a haematological analyser. All the monkeys developed a disease associated with macrocytic hypochromic anaemia characterised by a reduction in erythrocytes (RBC), haemoglobin (HB), haematocrit (HCT), mean cell volume (MCV), platelet count (PLT), and an increase in the red cell distribution width (RDW) and mean platelet volume (MPV). The clinical disease was characteristic of human African trypanosomiasis (HAT) with a pre-patent period of 3 days. Treatment with DA cleared trypanosomes from both the blood and cerebrospinal fluid (CSF). The parasites relapsed first in the CSF and later in the blood. This treatment normalised the RBC, HCT, HB, PLT, MCV, and MPV achieving the pre-infection values within two weeks while RDW took up to 6 weeks to attain pre-infection levels after treatment. Most of the parameters were later characterised by fluctuations, and declined at one to two weeks before relapse of trypanosomes in the haemolymphatic circulation. Following MelB treatment at 140 dpi, most values recovered within two weeks and stabilised at pre-infection levels, during the 223 days post treatment monitoring period. It is concluded that DA and MelB treatments cause similar normalising changes in the haematological profiles of monkeys infected with T. b. rhodesiense, indicating the efficacy of the drugs. The infection related changes in haematology parameters, further characterise the vervet monkey as an optimal induced animal model of HAT. Serial monitoring of these parameters can be used as an adjunct in the diagnosis and prognosis of the disease outcome in the vervet monkey model.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420376     DOI: 10.1016/j.actatropica.2011.02.013

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  9 in total

1.  Erythrina abyssinica prevents meningoencephalitis in chronic Trypanosoma brucei brucei mouse model.

Authors:  Johnson Nasimolo; Stephen Gitahi Kiama; Peter Karuri Gathumbi; Andrew Ndegwa Makanya; John Maina Kagira
Journal:  Metab Brain Dis       Date:  2014-01-23       Impact factor: 3.584

Review 2.  Passage of parasites across the blood-brain barrier.

Authors:  Willias Masocha; Krister Kristensson
Journal:  Virulence       Date:  2012-03-01       Impact factor: 5.882

3.  Development of a pHrodo-based assay for the assessment of in vitro and in vivo erythrophagocytosis during experimental trypanosomosis.

Authors:  Benoit Stijlemans; Jennifer Cnops; Peter Naniima; Axel Vaast; Viki Bockstal; Patrick De Baetselier; Stefan Magez
Journal:  PLoS Negl Trop Dis       Date:  2015-03-05

Review 4.  Tryps and trips: cell trafficking across the 100-year-old blood-brain barrier.

Authors:  Marina Bentivoglio; Krister Kristensson
Journal:  Trends Neurosci       Date:  2014-04-27       Impact factor: 13.837

5.  Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.

Authors:  John K Thuita; Kristina K Wolf; Grace A Murilla; Arlene S Bridges; David W Boykin; James N Mutuku; Qiang Liu; Susan K Jones; Charles O Gem; Shelley Ching; Richard R Tidwell; Michael Z Wang; Mary F Paine; Reto Brun
Journal:  PLoS Negl Trop Dis       Date:  2015-02-05

6.  Development of a safer laboratory vervet monkey model for the study of human African trypanosomiasis.

Authors:  Maxwell Waema; Naomi Maina; Simon Karanja; Beatrice Gachie; Maina Ngotho; John Kagira
Journal:  Afr J Lab Med       Date:  2014-10-29

7.  Early invasion of brain parenchyma by African trypanosomes.

Authors:  Ute Frevert; Alexandru Movila; Olga V Nikolskaia; Jayne Raper; Zachary B Mackey; Maha Abdulla; James McKerrow; Dennis J Grab
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

8.  Trypanosoma brucei rhodesiense infection in a Chinese traveler returning from the Serengeti National Park in Tanzania.

Authors:  Qin Liu; Xiao-Ling Chen; Mu-Xin Chen; Han-Guo Xie; Qing Liu; Zhu-Yun Chen; Yao-Ying Lin; Hua Zheng; Jia-Xu Chen; Yi Zhang; Xiao-Nong Zhou
Journal:  Infect Dis Poverty       Date:  2018-05-21       Impact factor: 4.520

Review 9.  Salivarian Trypanosomosis: A Review of Parasites Involved, Their Global Distribution and Their Interaction With the Innate and Adaptive Mammalian Host Immune System.

Authors:  Magdalena Radwanska; Nick Vereecke; Violette Deleeuw; Joar Pinto; Stefan Magez
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.